NovaQuest Pharma Opportunities Fund VI, L.P.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$90M
Investors
2
Min Invest
$30,000,000
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
NovaQuest Pharma Opportunities Fund VI, L.P. is a Cayman Islands limited partnership that first filed a Form D on April 18, 2023 and most recently amended it on June 12, 2024, describing itself as a private equity fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(7) and covers pooled investment fund interests. NovaQuest Pharma Opportunities Fund VI, L.P. reported $90,000,000 sold from 2 investors of a $800,000,000 total offering as of the Form D filed June 12, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $30,000,000. The Form D names Cotton Ginsberg Capital Partners Limited (CRD 12379917), associated with None; UCEA Capital Partners Ltd., associated with None; James Edward McCaffrey (CRD 2163581), associated with Innovation Partners, LLC; Innovation Partners, LLC (CRD 146344), associated with None and 1 other as recipients of sales compensation. Sales commissions are reported as $0 and finders' fees as $540,675. Form D allows these to be estimates. The issuer's address of record is 4208 Six Forks Road, Suite 920, Raleigh, NC 27609.
Critical Disclosures
What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.
Offering stalled · Form D · last filing June 12, 2024
Latest annual amendment reported no change in amount sold or investors
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Jun 12, 2024
Critical / warning
0 / 0
1 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
stalled
Latest event Stalled · Jun 12, 2024
SEC.govFund family Part of the NovaQuest Pharma Opportunities Fund family: 3 vehicles across 2 generations · adviser of record Novaquest Capital Management, L.L.C. · full family and the filing behind each link in the terminal
Investor
- The full fund family and any related vehicles (parallel, feeder, successor, sibling series) with the filing that shows each link
- 1 filing event with values and deltas, latest 2024-06-12, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Adviser of Record (Form ADV)
CRD 160359 · SEC-registered adviser · lists this fund on Schedule D 7.B.(1) as a private equity fund
Auditor named on Form ADV: BDO Cayman LTD · PCAOB-registered per the adviser
From the adviser's Form ADV as loaded from the SEC bulk data, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
NQ POF VI GP, L.P.
Executive Officer · Raleigh, NC
"The General Partner of the Issuer (the ""General Partner"")."
NQ POF VI GP, Ltd.
Executive Officer · Raleigh, NC
"The general partner of the General Partner (the ""GP LTD"")."
Ryan Applegate
Director · Raleigh, NC
Director of the GP LTD.
Ernest Gerald Brown
Director · Raleigh, NC
Director of the GP LTD.
Michael Gerald Bologna
Director · Raleigh, NC
Director of the GP LTD.
Carl Gerald Hellman
Director · Raleigh, NC
Director of the GP LTD.
Jonathan E. Tunnicliffe
Director · Raleigh, NC
Director of the GP LTD.
Patrick E. Jordan
Director · Raleigh, NC
Director of the GP LTD.
Hidekazu E. Tanaka
Director · Raleigh, NC
Director of the GP LTD.
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Cotton Ginsberg Capital Partners LimitedCRD 12379917 on BrokerCheck
Associated broker-dealer: None · London, X0 and outside the United States
UCEA Capital Partners Ltd.
Associated broker-dealer: None · London, X0 and outside the United States
James Edward McCaffreyCRD 2163581 on BrokerCheck
Associated broker-dealer: Innovation Partners, LLC (CRD 146344) · Charlotte, NC · Soliciting in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY and outside the United States
Innovation Partners, LLCCRD 146344 on BrokerCheck
Associated broker-dealer: None · Charlotte, NC · Soliciting in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY and outside the United States
Pimlico Partners FZCO
Associated broker-dealer: None · Dubai, C0 and outside the United States
Questions About NovaQuest Pharma Opportunities Fund VI, L.P.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is NovaQuest Pharma Opportunities Fund VI, L.P.?
NovaQuest Pharma Opportunities Fund VI, L.P. is a Cayman Islands limited partnership that filed a Form D with the SEC on June 12, 2024 as a private equity fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests.
Is NovaQuest Pharma Opportunities Fund VI, L.P. legit?
AltStreet does not rate legitimacy; it reports the public record. NovaQuest Pharma Opportunities Fund VI, L.P. filed a Form D with the SEC on June 12, 2024 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $90,000,000 sold to 2 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is NovaQuest Pharma Opportunities Fund VI, L.P. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that NovaQuest Pharma Opportunities Fund VI, L.P. claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has NovaQuest Pharma Opportunities Fund VI, L.P. raised?
NovaQuest Pharma Opportunities Fund VI, L.P. reported $90,000,000 sold from 2 investors of a $800,000,000 total offering as of the Form D filed June 12, 2024.
Who can invest in NovaQuest Pharma Opportunities Fund VI, L.P.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $30,000,000.
What is the minimum investment in NovaQuest Pharma Opportunities Fund VI, L.P.?
The Form D lists $30,000,000 as the minimum investment accepted from any outside investor as of June 12, 2024. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling NovaQuest Pharma Opportunities Fund VI, L.P. and how are they paid?
The Form D names Cotton Ginsberg Capital Partners Limited (CRD 12379917), associated with None; UCEA Capital Partners Ltd., associated with None; James Edward McCaffrey (CRD 2163581), associated with Innovation Partners, LLC; Innovation Partners, LLC (CRD 146344), associated with None and 1 other as recipients of sales compensation. Sales commissions are reported as $0 and finders' fees as $540,675. Form D allows these to be estimates.
Who is behind NovaQuest Pharma Opportunities Fund VI, L.P.?
The Form D lists 9 related persons: NQ POF VI GP, L.P., executive officer ("The General Partner of the Issuer (the ""General Partner"")."); NQ POF VI GP, Ltd., executive officer ("The general partner of the General Partner (the ""GP LTD"")."); Ryan Applegate, director (Director of the GP LTD); Ernest Gerald Brown, director (Director of the GP LTD); Michael Gerald Bologna, director (Director of the GP LTD); Carl Gerald Hellman, director (Director of the GP LTD); Jonathan E. Tunnicliffe, director (Director of the GP LTD); Patrick E. Jordan, director (Director of the GP LTD), and 1 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is NovaQuest Pharma Opportunities Fund VI, L.P. located?
The issuer's address on its SEC filings is 4208 Six Forks Road, Suite 920, Raleigh, NC 27609. Its phone number of record is 919-459-8620. It is organized under the laws of Cayman Islands.
How long is the NovaQuest Pharma Opportunities Fund VI, L.P. offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 3 amendments are on record for this CIK.
How large is NovaQuest Pharma Opportunities Fund VI, L.P.?
The Form D reports a revenue range of Not Applicable.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
